Deferiprone

(Ferriprox®)

Ferriprox®

Drug updated on 11/9/2023

Dosage FormTablet (oral; 500 mg, 1000 mg)
Drug ClassIron chelators
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias.

Product Monograph / Prescribing Information

Document TitleYearSource
Ferriprox (deferiprone) Prescribing Information.2021Chiesi USA, Inc., Cary, NC

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Guidelines for the management of transfusion dependent thalassaemia.2021Thalassaemia International Federation
Consensus statement of clinical care of patients with thalassemia in Canada.2018Canadian Hemoglobinopathy Association